The invention relates to compounds of formula (I): wherein n is 0, 1, 2 or 3； the pyrrolopyridine ring is a pyrrolo [3,2-b] pyridine group, a pyrrolo [3,2-c] pyridine group, a pyrrolo [2,3-c] pyridine group or a pyrrolo [2,3-b] group pyridine； the pyrrolopyridine ring being optionally substituted, in carbon position 4, 5, 6 and / or 7, with one or more substituents X, which are identical or different from one another； Z1, Z2, Z3, Z4 and Z5 represent, independently of one another, a hydrogen or halogen atom or a C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl- C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxyl, C1-C6-fluoroalkoxyl, cyano, C (O) NR1R2, nitro, NR1R2, C1-C6-thioalkyl, -S (O) -C1- C6-alkyl, -S (O) 2-C1-C6-alkyl, SO2NR1R2, NR3COR4, NR3SO2R5, aryl-C1-C6-alkylene or aryl, aryl and raryl-C1-C6-alkylene being optionally substituted； W represents a fused bicyclic group of the formula: (see formula II) attached to the nitrogen atom at the 1, 2, 3 or 4 positions； A represents an optionally substituted 5- to 7-membered heterocycle comprising from one to three heteroatoms selected from O, S or N； the basic state or acid addition salt, as well as the hydrate or solvate state. The invention also relates to a process for the preparation of said compounds of formula (I) and their therapeutic use. (see formula I)L'invention concerne des composé de formule (l): dans laquelle n est égal à 0, 1, 2 ou 3； le noyau pyrrolopyridine est un groupe pyrrolo[3,2-b]pyridine, un groupe pyrrolo[3,2-c]pyridine, un groupe pyrrolo[2,3-c]pyridine ou un groupe pyrrolo[2,3-b] pyridine； le noyau pyrrolopyridine étant éventuellement substitué, en position carbonée 4, 5, 6 et/ou 7, par un ou plusieurs substituents X, identiques ou différents l'un de l'autre； Z1, Z2, Z3, Z4 et Z5 représentent, indépendamment l'un de l'autre, un atome d'hydrogène ou d'halogène ou un groupe C1-C6-alkyle, C3-C7-cycloalkyle, C3-C7-cycloalkyle-C1-C3-alkylène, C1-C6-fluoroalkyle, C1-C6-alcoxyle, C1-C6-fluoroalcoxyle,
